AU5894386A - Membrane anchor/active compound conjugate, its preparation and its use - Google Patents

Membrane anchor/active compound conjugate, its preparation and its use

Info

Publication number
AU5894386A
AU5894386A AU58943/86A AU5894386A AU5894386A AU 5894386 A AU5894386 A AU 5894386A AU 58943/86 A AU58943/86 A AU 58943/86A AU 5894386 A AU5894386 A AU 5894386A AU 5894386 A AU5894386 A AU 5894386A
Authority
AU
Australia
Prior art keywords
active ingredient
preparation
active compound
membrane anchor
compound conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU58943/86A
Other versions
AU611385B2 (en
Inventor
Gerhard Becker
Wolfgang Bessleer
Hans-Jorg Buhring
Gunther Jung
Jorg Metzger
Karl-Heinz Wiesmuller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU5894386A publication Critical patent/AU5894386A/en
Application granted granted Critical
Publication of AU611385B2 publication Critical patent/AU611385B2/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Alteration of Name(s) in Register under S187 Assignors: HOECHST AKTIENGESELLSCHAFT
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Conjugates are described in which the active ingredient is covalently bonded to the anchoring membrane, which is a compound of the formulae <IMAGE> in which A can be: sulphur, oxygen, disulphide (-S-S-), methylene (-CH2-) or -NH-; n = 0 to 5; m = 1 or 2; C* = an asymmetric carbon atom of R or S configuration, R, R' and R'' are identical or different and are an alkyl, alkenyl or alkynyl group having 7 to 25 carbon atoms or are hydrogen which can optionally be substituted by hydroxyl, amino, oxo, acyl, alkyl or cycloalkyl groups and R1 and R2 are identical or different and are defined as R, R' or R'' or can be -OR, -OCOR, -COOR, -NHCOR or -CONHR and X is an active ingredient or a spacer active ingredient group. The anchoring membrane active ingredient conjugates increase antibody formation.
AU58943/86A 1985-06-24 1986-06-23 Membrane anchor/active compound conjugate, its preparation and its use Expired AU611385B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3522512 1985-06-24
DE3522512 1985-06-24
DE3546150 1985-12-27
DE19853546150 DE3546150A1 (en) 1985-06-24 1985-12-27 MEMBRANE ANCHOR ACTIVE CONJUGATE, ITS PRODUCTION AND USE

Publications (2)

Publication Number Publication Date
AU5894386A true AU5894386A (en) 1987-01-08
AU611385B2 AU611385B2 (en) 1991-06-13

Family

ID=25833375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58943/86A Expired AU611385B2 (en) 1985-06-24 1986-06-23 Membrane anchor/active compound conjugate, its preparation and its use

Country Status (12)

Country Link
EP (1) EP0210412B1 (en)
JP (1) JP2594259B2 (en)
KR (1) KR930008091B1 (en)
AT (1) ATE131491T1 (en)
AU (1) AU611385B2 (en)
CA (1) CA1340656C (en)
DE (2) DE3546150A1 (en)
DK (1) DK172399B1 (en)
ES (1) ES8801677A1 (en)
FI (1) FI94419C (en)
NO (1) NO174207C (en)
PT (1) PT82826B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010348A1 (en) * 1988-04-19 1989-11-02 Synpharm Ltd Fatty amino acids, and homo- and hetero-oligomers and conjugates thereof
AU612130B2 (en) * 1987-01-05 1991-07-04 Hoechst Aktiengesellschaft A process for the preparation of lipophilic amino acid derivatives, and lipophilic amino acid derivatives
AU619826B2 (en) * 1988-04-22 1992-02-06 Aventis Pharma Deutschland Gmbh A synthetic vaccine against foot and mouth disease and a process for the preparation thereof
US5874083A (en) * 1986-04-21 1999-02-23 Bioenterprises Pty Limited Immunopotentiating complexes comprising TraT proteins
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937412A1 (en) * 1989-11-10 1991-05-16 Hoechst Ag SYNTHETIC VACCINE FOR THE SPECIFIC INDUCTION OF CYTOTOXIC T-LYMPHOZYTES
US6024964A (en) * 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6074650A (en) * 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
AU619443B2 (en) * 1986-04-21 1992-01-30 Bioenterprises Pty. Ltd. Immunopotentiation
JPS63107742A (en) * 1986-05-20 1988-05-12 Wako Pure Chem Ind Ltd Novel functional liposome and its preparation
US5120829A (en) * 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
EP0485563B1 (en) * 1990-05-30 1994-12-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Polyether-substituted tumor agents
DE4119856A1 (en) * 1991-06-17 1992-12-24 Hoechst Ag N-ACYL-S- (2-HYDROXYALKYL) -CYSTEINS, THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF SYNTHETIC IMMUNE ADJUVANTS AND SYNTHETIC VACCINANTS
EP0604945A1 (en) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, its derivatives, production and use thereof
AU666789B2 (en) * 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
DE4325317C2 (en) * 1993-07-29 1998-05-20 Univ Dresden Tech Process for the radioactive labeling of immunoglobulins
DE4329309A1 (en) * 1993-08-31 1995-03-09 Rapp Polymere Gmbh Lipopeptide compounds
EP0641776A3 (en) * 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
FR2727117A1 (en) * 1994-11-18 1996-05-24 Geffard Michel USE OF POLYLYSIN CONJUGATES FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES AND DEGENERATIVE DISORDERS OF AUTOIMMUN CHARACTER
US6117940A (en) * 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
IL131266A0 (en) * 1999-08-05 2001-01-28 N S T Neurosurvival Technologi Peptides and pharmaceutical compositions comprising same
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
GB9915074D0 (en) * 1999-06-28 1999-08-25 Cortecs Plc Ligand-binding composition
DE102009034779A1 (en) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetic analogues of bacterial lipopeptides and their application for the therapy and prophylaxis of allergic diseases
EA031379B1 (en) * 2010-03-23 2018-12-28 Новартис Аг Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
DE102011018499A1 (en) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin
WO2014055754A1 (en) * 2012-10-05 2014-04-10 The University Of Kansas Conformationally-constrained kinked endosomal-disrupting peptides
US10766928B2 (en) 2012-10-05 2020-09-08 The University Of Kansas Targeted conformationally-constrained kinked endosomal disrupting peptides
WO2015163488A1 (en) * 2014-04-25 2015-10-29 Ajinomoto Co., Inc. Immunostimulating agent
DE102016005550B4 (en) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvant to induce a cellular immune response
KR102665710B1 (en) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 GLP-1 composition and its uses
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As Glp-1 compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000330B1 (en) * 1977-06-20 1981-08-05 Ciba-Geigy Ag Lipopeptides, process for their preparation and pharmaceutical compositions containing them
US4125569A (en) 1977-08-25 1978-11-14 Mobil Oil Corporation Process for increasing hydrogenation rate of polymerized n-alphaolefins
EP0014815A3 (en) * 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptide derivatives, process for their preparation and intermediates, and pharmaceutical compositions containing one of these compounds
EP0114787B1 (en) * 1983-01-25 1991-09-25 Ciba-Geigy Ag Peptide derivatives

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874083A (en) * 1986-04-21 1999-02-23 Bioenterprises Pty Limited Immunopotentiating complexes comprising TraT proteins
AU612130B2 (en) * 1987-01-05 1991-07-04 Hoechst Aktiengesellschaft A process for the preparation of lipophilic amino acid derivatives, and lipophilic amino acid derivatives
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
WO1989010348A1 (en) * 1988-04-19 1989-11-02 Synpharm Ltd Fatty amino acids, and homo- and hetero-oligomers and conjugates thereof
AU619826B2 (en) * 1988-04-22 1992-02-06 Aventis Pharma Deutschland Gmbh A synthetic vaccine against foot and mouth disease and a process for the preparation thereof

Also Published As

Publication number Publication date
DK294086A (en) 1986-12-25
FI862631A0 (en) 1986-06-19
NO862511D0 (en) 1986-06-23
KR870000359A (en) 1987-02-18
DE3650448D1 (en) 1996-01-25
AU611385B2 (en) 1991-06-13
NO174207C (en) 1994-03-30
EP0210412A2 (en) 1987-02-04
DK172399B1 (en) 1998-05-18
ES8801677A1 (en) 1988-02-16
KR930008091B1 (en) 1993-08-25
JP2594259B2 (en) 1997-03-26
EP0210412A3 (en) 1990-02-07
FI862631A (en) 1986-12-25
PT82826B (en) 1989-01-17
JPS6263600A (en) 1987-03-20
FI94419C (en) 1995-09-11
ES556417A0 (en) 1988-02-16
PT82826A (en) 1986-07-01
ATE131491T1 (en) 1995-12-15
EP0210412B1 (en) 1995-12-13
NO174207B (en) 1993-12-20
CA1340656C (en) 1999-07-20
DE3546150A1 (en) 1987-01-22
DK294086D0 (en) 1986-06-23
NO862511L (en) 1986-12-29
FI94419B (en) 1995-05-31

Similar Documents

Publication Publication Date Title
AU5894386A (en) Membrane anchor/active compound conjugate, its preparation and its use
FI905575A0 (en) NY POLYPEPTIDFOERENING OCH FOERFARANDE FOER DESS FRAMSTAELLNING.
PT79735A (en) 11BETA-ARYL ESTRADIENES OF THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
ES8707520A1 (en) Pyridonecarboxylic acid derivatives.
KR890014098A (en) Prophylaxis and treatment of central neurodegenerative diseases containing catechol amine derivatives
KR940021059A (en) Lipid metabolism improvers
ES539683A0 (en) PROCEDURE FOR THE PREPARATION OF 6,6-ETILEN-15,16-METI- LEN-3-OXO-17 &amp; -PREGN-4-EN-21,17-CARBOLACTONES
FR2649110B1 (en) NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
SE8703032L (en) PERCUTANEOUS ADMINISTRATION OF MEDICINAL PRODUCTS
IE901350L (en) Diaminoethylene compounds
DE69624121D1 (en) MEMBRANES POSSENDING SECOND MESSENGERS
IE780234L (en) Oleandomycin derivatives
ES8704918A1 (en) Phosphate ester derivatives, and their use as anti-cancer agents.
ATE43594T1 (en) 3-ALKOXY-2-(N-PYRROLIDINO)-N-PYRIDYL-N-FURYL(OD R THIENYL)-METHYL-PROPYLAMINE, THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM.
KR870700071A (en) Vitamin D derivatives and preparation method thereof
KR880012232A (en) Anti-obesity agents
BR9610229A (en) Polyhydroxyalkylamidamine oxides
WO1994012490A3 (en) Amide derivatives and dermatologic preparations containing the same
ATE63305T1 (en) NEW CARBACYCLINES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS MEDICINES.

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER OWNER WAS: HOECHST AKTIENGESELLSCHAFT